Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody drug conjugate (RG6109) Antibody drug conjugate (RG6148) Anti-MUC16 TDC (RG7882) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF MAb) CD20-TCB (RG6026) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cibisatamab (CEA/CD3 biMAb) (RG7802) Cobimetinib (MEK inhibitor) (RG7421) Codrituzumab (anti–glypican 3 MAb) (CHU, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib (ROS1/TRK inhibitor) (RXDX-101, RG6268) FAP-4-1BBL FP (RG7827) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Fixed dose combination SC pertuzumab + trastuzumab Glypican-3/CD3 biMAb (CHU) HER2/CD3-TDB (RG6194) Idasanutlin (MDM2 antagonist) (RG7388) Individualized NeoAntigen Specific Immunotherapy (iNeST) (RG6180) Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6123) Monoclonal antibody (RG6160) Mosunetuzumab (CD20/CD3 biMAb) (RG7828) Obinutuzumab Pan-RAF inhibitor (RG6185) PD1-TIM3 b1MAb (RG7769) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor (CHU) Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Tiragolumab (anti-TIGIT MAb) (RG6058) Vanucizumab (ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Breast, Gastrointestinal, Genitourinary

Phase:

Region:

Molecule: Ipatasertib (AKT inhibitor) (GDC-0068, RG7440)

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel AU NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel AU
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CA NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CA
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel ES NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel ES
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel FR NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel FR
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel GB NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel GB
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
1 of 5 clinical trials
1-4 of 5 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK